Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- July31 2004
- Volume 11
- Issue 14
News You Can Use: Lots of Lobbying
Advertisement
Who spends the most money on lobbying activities in Washington, DC? Health care is well represented—or is it? Many physicians wonder if their interests are really being addressed in the nation's Capitol. According to the National Journal, the following were the top 10 influence peddlers in 2003:
Entity / 2003 Spending ($ million)
AARP / 20.8
US Chamber Institute for Legal Reform / 18.0
American Medical Association / 17.3
General Electric / 17.2
US Chamber of Commerce / 16.5
Pharmaceutical Manufacturers Research Association / 16.0
Freddie Mac / 15.8
Altria (formerly Philip Morris) / 12.4
American Hospital Association / 12.4
Edison Electric Institute / 12.0
Articles in this issue
about 18 years ago
Blend the Money in Your Blended Familyabout 18 years ago
Build College Savings Earlyabout 18 years ago
Think Positive and Success Will Followabout 18 years ago
Popping the Questionabout 18 years ago
More Retirement Plansabout 18 years ago
Canceling Cheap Ticketsabout 18 years ago
Your Average Deductionabout 18 years ago
Avoiding Probate Fightsabout 18 years ago
Ask Your Brokerabout 18 years ago
Scandal Bypasses CongressAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5